Cargando…

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

INTRODUCTION: Somatic inactivation of the TP53 gene in breast tumors is a marker for poor outcome, and breast cancer outcome might also be affected by germ-line variation in the TP53 gene or its regulators. We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G&...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Marjanka K, Tommiska, Johanna, Broeks, Annegien, van Leeuwen, Flora E, Van't Veer, Laura J, Pharoah, Paul DP, Easton, Douglas F, Shah, Mitul, Humphreys, Manjeet, Dörk, Thilo, Reincke, Scarlett A, Fagerholm, Rainer, Blomqvist, Carl, Nevanlinna, Heli
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815553/ https://www.ncbi.nlm.nih.gov/pubmed/20021639 http://dx.doi.org/10.1186/bcr2460

Ejemplares similares

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009)

Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death
por: Rosso, Melissa, et al.
Publicado: (2015)

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
por: Olsson, Hans, et al.
Publicado: (2013)

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
por: Scott, Rodney J
Publicado: (2010)

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
por: Fagerholm, Rainer, et al.
Publicado: (2017)

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models
por: Faur, N, et al.
Publicado: (2009)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis
por: Duan, Xiaohua, et al.
Publicado: (2017)

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
por: YONEDA, TOMOKO, et al.
Publicado: (2013)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore
por: Chua, Hui Wan, et al.
Publicado: (2010)

The frequency of TP53 R72P and MDM2 309T>G polymorphisms in Iranian infertile men with spermatogenetic failure: A case-control study
por: Ebrahim Abadi, Zeinab, et al.
Publicado: (2018)

Drug discovery in the p53 pathway
por: Lane, DP, et al.
Publicado: (2000)

Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
por: Gorgoulis, V. G., et al.
Publicado: (1998)

Mdm2 RING Mutation Enhances p53 Transcriptional Activity and p53-p300 Interaction
por: Clegg, Hilary V., et al.
Publicado: (2012)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Evolution of the p53-MDM2 pathway
por: Åberg, Emma, et al.
Publicado: (2017)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity
por: Pant, Vinod, et al.
Publicado: (2013)

p53 isoforms change p53 paradigm
por: Bourdon, JC
Publicado: (2014)

Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity
por: Pant, Vinod, et al.
Publicado: (2014)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

p53 β-hydroxybutyrylation attenuates p53 activity
por: Liu, Kun, et al.
Publicado: (2019)

Understanding p53 functions through p53 antibodies
por: Sabapathy, Kanaga, et al.
Publicado: (2019)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

The RP-Mdm2-p53 Pathway and Tumorigenesis
por: Miliani de Marval, Paula L., et al.
Publicado: (2011)

Controlling the Mdm2-Mdmx-p53 Circuit
por: Waning, David L., et al.
Publicado: (2010)

Immunohistochemical detection of P53 and Mdm2 in vitiligo
por: Bakry, Ola A., et al.
Publicado: (2012)

Heterogeneous Hydration of p53/MDM2 Complex
por: Guo, Zuojun, et al.
Publicado: (2014)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions
por: Blackburn, Tim J., et al.
Publicado: (2013)

NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
por: Liu, Xiaofeng, et al.
Publicado: (2016)

EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction
por: Zhao, Jing, et al.
Publicado: (2021)

Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
por: Lai, Chunwei W., et al.
Publicado: (2022)

Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway
por: Hu, Min, et al.
Publicado: (2006)

D133P53, directly transactivated by p53, prevents p53-mediated apoptosis without inhibiting p53-mediated cell cycle arrest
por: Aoubala, M, et al.
Publicado: (2010)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5q5kfetfvi3h13hoh2jd80r1ij